Evidence for magnesium sulfate as a tocolytic agent

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Clinical Trials

Background:

• Acute tocolysis aims to delay preterm birth, with various agents investigated for efficacy and safety.
• Magnesium sulfate (MgSO4) is a commonly used tocolytic agent, but its comparative effectiveness requires quantitative evaluation.

Purpose of the Study:

• To quantitatively assess the efficacy and side effects of magnesium sulfate (MgSO4) for acute tocolysis.
• To compare MgSO4 against placebo and beta-agonist agents using evidence from randomized trials.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) identified via MEDLINE and other sources.
• Quality evaluation and data abstraction performed by two independent, blinded investigators.
• Statistical analysis included random effects modeling for odds ratios and 95% confidence intervals; heterogeneity assessed using Q statistic.

Main Results:

• No significant difference was observed between magnesium sulfate (MgSO4) and placebo for any delivery delay outcomes.
• Magnesium sulfate (MgSO4) demonstrated comparable efficacy to beta-agonists (e.g., ritodrine) in achieving clinically significant tocolysis.
• A significant difference was found in the frequency of medication discontinuation due to side effects, favoring beta-agonists over MgSO4.

Conclusions:

• Limited data exist comparing magnesium sulfate (MgSO4) to placebo for acute tocolysis.
• Magnesium sulfate (MgSO4) appears comparable to beta-agonists for tocolysis, though not sufficient for definitive agent selection.
• Further research is needed to establish optimal agent choice, considering efficacy and side effect profiles.